Amidst the tumult of the health care market, opportunities arise to seize undervalued stocks.

Examining the Relative Strength Index (RSI) unveils a stock’s momentum, aiding in predicting short-term performance. When the RSI dips below 30, a stock is deemed oversold, as per market experts.

Here’s a rundown of notable, oversold contenders in the health care sector:

Progyny Inc

• Reports on Sept. 19 detailed a client opting to sever ties with Progyny. This news precipitated a 32% decline in the company’s stock over five days, hitting a 52-week low of $13.93.
• RSI Value: 26.50
• PGNY Price Action: Progyny’s shares inched up by 1% to close at $16.62 on Friday.

Indivior PLC

• On Sept. 4, Indivior unveiled updates on Aelis Farma’s Phase 2B study related to cannabis use disorder. The stock hit a 52-week low of $9.14.
• RSI Value: 25.92
• INDV Price Action: Indivior shares slipped by 2.1% to settle at $9.48 on Friday.

Moderna Inc

• Moderna made waves on Sept. 17, as Health Canada greenlit its SPIKEVAX vaccine against COVID-19, primarily targeting the KP.2 variant. The company plans to distribute the vaccine promptly. Dr. Shehzad Iqbal, Moderna Canada’s country medical director, emphasized the importance of vaccination amidst escalating COVID-19 cases. Throughout the last month, Moderna’s shares decreased by 20%, reaching a 52-week low of $62.55.
• RSI Value: 28.17
• MRNA Price Action: Moderna shares dipped by 3.4% to close at $65.69 on Friday.

Will these health care stocks bounce back from their recent lows, or is there more turbulence ahead? Only time will tell in the unpredictable world of stock markets.